TipRanks
Advertisement
Advertisement

KROS Stock Latest News

Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play
Company AnnouncementsKeros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play
1d ago
KROS
Keros Therapeutics earns milestone for Phase 3 myelofibrosis trial
PremiumCompany Announcements
Keros Therapeutics earns milestone for Phase 3 myelofibrosis trial
2d ago
8K
KROS
Keros Therapeutics to receive $20M development milestone payment from Takeda
PremiumThe Fly
Keros Therapeutics to receive $20M development milestone payment from Takeda
2d ago
TAK
KROS
Keros Begins Phase 2 Rinvatercept Trial in DMD
PremiumCompany Announcements
Keros Begins Phase 2 Rinvatercept Trial in DMD
3d ago
8K
KROS
Keros announces first patient dosed in Phase 2 trial of rinvatercept
PremiumThe Fly
Keros announces first patient dosed in Phase 2 trial of rinvatercept
3d ago
KROS
Keros Therapeutics files $350M mixed securities shelf
PremiumThe FlyKeros Therapeutics files $350M mixed securities shelf
21d ago
KROS
Keros Therapeutics Announces Share Repurchase Authorization Program
Premium
Company Announcements
Keros Therapeutics Announces Share Repurchase Authorization Program
23d ago
8K
KROS
Keros Therapeutics announces $5M share repurchase program after Takeda payment
Premium
The Fly
Keros Therapeutics announces $5M share repurchase program after Takeda payment
23d ago
TAK
KROS
Keros Therapeutics price target lowered to $17 from $20 at BofA
PremiumThe Fly
Keros Therapeutics price target lowered to $17 from $20 at BofA
2M ago
KROS
Hold Rating Maintained as Pipeline Progress Offsets Long-Term Uncertainty; Price Target Reaffirmed at $16
PremiumRatings
Hold Rating Maintained as Pipeline Progress Offsets Long-Term Uncertainty; Price Target Reaffirmed at $16
2M ago
KROS
Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo
PremiumThe Fly
Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo
2M ago
KROS
Keros Therapeutics price target lowered to $23 from $30 at Leerink
PremiumThe Fly
Keros Therapeutics price target lowered to $23 from $30 at Leerink
2M ago
KROS
Keros updates TGF-β pipeline strategy in new presentation
PremiumCompany AnnouncementsKeros updates TGF-β pipeline strategy in new presentation
2M ago
8K
KROS
Keros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24)
Premium
The Fly
Keros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24)
2M ago
KROS
Keros Therapeutics Earns Milestone Payment for Elritercept Trial
Premium
Company Announcements
Keros Therapeutics Earns Milestone Payment for Elritercept Trial
2M ago
8K
KROS
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
PremiumThe Fly
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
2M ago
TAK
KROS
Keros Therapeutics Announces CFO Resignation and Interim Successor
PremiumCompany Announcements
Keros Therapeutics Announces CFO Resignation and Interim Successor
2M ago
8K
KROS
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
PremiumCompany Announcements
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
3M ago
KROS
Keros Therapeutics Appoints Anne Prener to Board
PremiumCompany Announcements
Keros Therapeutics Appoints Anne Prener to Board
3M ago
8K
KROS
Keros Therapeutics Stockholders Approve Directors and Governance Matters
PremiumCompany AnnouncementsKeros Therapeutics Stockholders Approve Directors and Governance Matters
4M ago
8K
KROS
Keros Therapeutics CEO to Present at Goldman Sachs Conference
Premium
Company Announcements
Keros Therapeutics CEO to Present at Goldman Sachs Conference
4M ago
8K
KROS
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
Premium
Ratings
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
5M ago
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >